A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

NCT01713530 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec/insulin aspart
DRUG: insulin degludec
DRUG: insulin aspart

Sponsor

Novo Nordisk A/S